The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study | Zendy

Shahrbanoo Rostami | Zendy; Ahmad Kazemi | Zendy; Bahram Chahardouli | Zendy; Saeed Mohammadi | Zendy; Mohsen Nikbakht | Zendy; Nasrin Alizadeh | Zendy; Asadollah Mousavi | Zendy; Kamran Alimoghaddam | Zendy; Majid Teremmahi Ardestani | Zendy

Open Access

The Prognostic Impact of WT1 Expression Levels, Mutations, and SNP rs16754 in AML Patients: A Retrospective Cohort Study

Author(s) -

Shahrbanoo Rostami,

Ahmad Kazemi,

Bahram Chahardouli,

Saeed Mohammadi,

Mohsen Nikbakht,

Nasrin Alizadeh,

Asadollah Mousavi,

Kamran Alimoghaddam,

Majid Teremmahi Ardestani

Publication year - 2020

Publication title -

journal of advances in medical and biomedical research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.113

H-Index - 12

ISSN - 2676-6264

DOI - 10.30699/jambs.29.133.109

Subject(s) - retrospective cohort study , snp , oncology , cohort , medicine , genetics , single nucleotide polymorphism , biology , genotype , gene

10.30699/jambs.29.133.109 Background & Objective: The clinical outcomes and treatment options for acute myeloid leukemia (AML) patients are highly dependent upon molecular markers. In this study, Wilms tumor 1 (WT1) (exons 7 and 9) mutations, single-nucleotide polymorphism (SNP) rs16754, and WT1 expression levels in 130 random AML patients were screened; FMs-like tyrosine kinase-3 internal tandem duplication (FLT3-ITD), nucleophosmin (NPM1), and CCAAT/enhancer-binding protein alpha (CEBPA) mutations were also evaluated.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research